EGFR and non-small cell lung carcinoma: Given that gefitinib showed an advantage in improving efficacy and reducing toxicity for patients with NSCLC, it was recommended as a first-line treatment for NSCLC patients with sensitive mutations in the EGFR gene in July 2015.